Prostaglandin E2 augments IL-10 signaling and function

Hyeon Joo Cheon, Young Hee Rho, Sungjae Choi, Young Ho Lee, Gwan Gyu Song, Jeongwon Sohn, Nam Hee Won, Jong Dae Ji

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

In inflamed joints of rheumatoid arthritis, PGE2 is highly expressed, and IL-10 and IL-6 are also abundant. PGE2 is a well-known activator of the cAMP signaling pathway, and there is functional cross-talk between cAMP signaling and the Jak-STAT signaling pathway. In this study, we evaluated the modulating effect of PGE2 on STAT signaling and its biological function induced by IL-10 and IL-6, and elucidated its mechanism in THP-1 cells. STAT phosphorylation was determined by Western blot, and gene expression was analyzed using real-time PCR. Pretreatment with PGE2 significantly augmented IL-10-induced STAT3 and STAT1 phosphorylation, as well as suppressors of cytokine signaling 3 (SOCS3) and IL-1R antagonist gene expression. In contrast, PGE2 suppressed IL-6-induced phosphorylation of STAT3 and STAT1. These PGE2-induced modulating effects were largely reversed by actinomycin D. Pretreatment with dibutyryl cAMP augmented IL-10-induced, but did not change DL-6-induced STAT3 phosphorylation. Misoprostol, an EP2/3/4 agonist, and butaprost, an EP2 agonist, augmented IL-10-induced STAT3 phosphorylation and SOCS3 gene expression, but sulprostone, an EP1/3 agonist, had no effect H89, a protein kinase A inhibitor, and LY294002, a PI3K inhibitor, diminished PGE2-mediated augmentation of IL-10-induced STAT3 phosphorylation. In this study, we found that PGE 2 selectively regulates cytokine signaling via increased intracellular cAMP levels and de novo gene expression, and these modulating effects may be mediated through EP2 or EP4 receptors. PGE2 may modulate immune responses by alteration of cytokine signaling in THP-1 cells.

Original languageEnglish
Pages (from-to)1092-1100
Number of pages9
JournalJournal of Immunology
Volume177
Issue number2
DOIs
Publication statusPublished - 2006 Jul 15

Fingerprint

Dinoprostone
Interleukin-10
Phosphorylation
Cytokines
Gene Expression
Interleukin-6
Misoprostol
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Interleukin-3
Dactinomycin
Protein Kinase Inhibitors
Cyclic AMP-Dependent Protein Kinases
Prostaglandins E
Phosphatidylinositol 3-Kinases
Real-Time Polymerase Chain Reaction
Rheumatoid Arthritis
Joints
Western Blotting

ASJC Scopus subject areas

  • Immunology

Cite this

Prostaglandin E2 augments IL-10 signaling and function. / Cheon, Hyeon Joo; Rho, Young Hee; Choi, Sungjae; Lee, Young Ho; Song, Gwan Gyu; Sohn, Jeongwon; Won, Nam Hee; Ji, Jong Dae.

In: Journal of Immunology, Vol. 177, No. 2, 15.07.2006, p. 1092-1100.

Research output: Contribution to journalArticle

@article{2943118322ac488db102c224525be30a,
title = "Prostaglandin E2 augments IL-10 signaling and function",
abstract = "In inflamed joints of rheumatoid arthritis, PGE2 is highly expressed, and IL-10 and IL-6 are also abundant. PGE2 is a well-known activator of the cAMP signaling pathway, and there is functional cross-talk between cAMP signaling and the Jak-STAT signaling pathway. In this study, we evaluated the modulating effect of PGE2 on STAT signaling and its biological function induced by IL-10 and IL-6, and elucidated its mechanism in THP-1 cells. STAT phosphorylation was determined by Western blot, and gene expression was analyzed using real-time PCR. Pretreatment with PGE2 significantly augmented IL-10-induced STAT3 and STAT1 phosphorylation, as well as suppressors of cytokine signaling 3 (SOCS3) and IL-1R antagonist gene expression. In contrast, PGE2 suppressed IL-6-induced phosphorylation of STAT3 and STAT1. These PGE2-induced modulating effects were largely reversed by actinomycin D. Pretreatment with dibutyryl cAMP augmented IL-10-induced, but did not change DL-6-induced STAT3 phosphorylation. Misoprostol, an EP2/3/4 agonist, and butaprost, an EP2 agonist, augmented IL-10-induced STAT3 phosphorylation and SOCS3 gene expression, but sulprostone, an EP1/3 agonist, had no effect H89, a protein kinase A inhibitor, and LY294002, a PI3K inhibitor, diminished PGE2-mediated augmentation of IL-10-induced STAT3 phosphorylation. In this study, we found that PGE 2 selectively regulates cytokine signaling via increased intracellular cAMP levels and de novo gene expression, and these modulating effects may be mediated through EP2 or EP4 receptors. PGE2 may modulate immune responses by alteration of cytokine signaling in THP-1 cells.",
author = "Cheon, {Hyeon Joo} and Rho, {Young Hee} and Sungjae Choi and Lee, {Young Ho} and Song, {Gwan Gyu} and Jeongwon Sohn and Won, {Nam Hee} and Ji, {Jong Dae}",
year = "2006",
month = "7",
day = "15",
doi = "10.4049/jimmunol.177.2.1092",
language = "English",
volume = "177",
pages = "1092--1100",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Prostaglandin E2 augments IL-10 signaling and function

AU - Cheon, Hyeon Joo

AU - Rho, Young Hee

AU - Choi, Sungjae

AU - Lee, Young Ho

AU - Song, Gwan Gyu

AU - Sohn, Jeongwon

AU - Won, Nam Hee

AU - Ji, Jong Dae

PY - 2006/7/15

Y1 - 2006/7/15

N2 - In inflamed joints of rheumatoid arthritis, PGE2 is highly expressed, and IL-10 and IL-6 are also abundant. PGE2 is a well-known activator of the cAMP signaling pathway, and there is functional cross-talk between cAMP signaling and the Jak-STAT signaling pathway. In this study, we evaluated the modulating effect of PGE2 on STAT signaling and its biological function induced by IL-10 and IL-6, and elucidated its mechanism in THP-1 cells. STAT phosphorylation was determined by Western blot, and gene expression was analyzed using real-time PCR. Pretreatment with PGE2 significantly augmented IL-10-induced STAT3 and STAT1 phosphorylation, as well as suppressors of cytokine signaling 3 (SOCS3) and IL-1R antagonist gene expression. In contrast, PGE2 suppressed IL-6-induced phosphorylation of STAT3 and STAT1. These PGE2-induced modulating effects were largely reversed by actinomycin D. Pretreatment with dibutyryl cAMP augmented IL-10-induced, but did not change DL-6-induced STAT3 phosphorylation. Misoprostol, an EP2/3/4 agonist, and butaprost, an EP2 agonist, augmented IL-10-induced STAT3 phosphorylation and SOCS3 gene expression, but sulprostone, an EP1/3 agonist, had no effect H89, a protein kinase A inhibitor, and LY294002, a PI3K inhibitor, diminished PGE2-mediated augmentation of IL-10-induced STAT3 phosphorylation. In this study, we found that PGE 2 selectively regulates cytokine signaling via increased intracellular cAMP levels and de novo gene expression, and these modulating effects may be mediated through EP2 or EP4 receptors. PGE2 may modulate immune responses by alteration of cytokine signaling in THP-1 cells.

AB - In inflamed joints of rheumatoid arthritis, PGE2 is highly expressed, and IL-10 and IL-6 are also abundant. PGE2 is a well-known activator of the cAMP signaling pathway, and there is functional cross-talk between cAMP signaling and the Jak-STAT signaling pathway. In this study, we evaluated the modulating effect of PGE2 on STAT signaling and its biological function induced by IL-10 and IL-6, and elucidated its mechanism in THP-1 cells. STAT phosphorylation was determined by Western blot, and gene expression was analyzed using real-time PCR. Pretreatment with PGE2 significantly augmented IL-10-induced STAT3 and STAT1 phosphorylation, as well as suppressors of cytokine signaling 3 (SOCS3) and IL-1R antagonist gene expression. In contrast, PGE2 suppressed IL-6-induced phosphorylation of STAT3 and STAT1. These PGE2-induced modulating effects were largely reversed by actinomycin D. Pretreatment with dibutyryl cAMP augmented IL-10-induced, but did not change DL-6-induced STAT3 phosphorylation. Misoprostol, an EP2/3/4 agonist, and butaprost, an EP2 agonist, augmented IL-10-induced STAT3 phosphorylation and SOCS3 gene expression, but sulprostone, an EP1/3 agonist, had no effect H89, a protein kinase A inhibitor, and LY294002, a PI3K inhibitor, diminished PGE2-mediated augmentation of IL-10-induced STAT3 phosphorylation. In this study, we found that PGE 2 selectively regulates cytokine signaling via increased intracellular cAMP levels and de novo gene expression, and these modulating effects may be mediated through EP2 or EP4 receptors. PGE2 may modulate immune responses by alteration of cytokine signaling in THP-1 cells.

UR - http://www.scopus.com/inward/record.url?scp=33745834002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745834002&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.177.2.1092

DO - 10.4049/jimmunol.177.2.1092

M3 - Article

C2 - 16818766

AN - SCOPUS:33745834002

VL - 177

SP - 1092

EP - 1100

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -